Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Scheiermann, Patrick ^a,b   Bachmann, Malte ^a   Härdle, Lorena ^a   Pleli, Thomas ^a   Piiper, Albrecht ^a   Zwissler, Bernhard ^b   Pfeilschifter, Josef ^a   Mühl, Heiko ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IL1F9 PROTEIN, MOUSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN-36 RECEPTOR, MOUSE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PARACETAMOL;

ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENDOTOXEMIA; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL; MALE; METABOLISM; MOUSE; PATHOLOGY;

ACETAMINOPHEN; ANIMALS; CHEMOKINE CCL20; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; ENDOTOXEMIA; GENE EXPRESSION REGULATION; HEPATOCYTES; INTERLEUKIN-1; MALE; MICE; RECEPTORS, INTERLEUKIN-1;

EID: 84923384574     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08521     Document Type: Article

References (60)

1. Bernau, W., Auzinger, G., Dhawan, A. & Wendon, J. Acute liver failure. Lancet 376, 190-201 (2010).
2. Kubes, P. & Mehal, W. Z. Sterile inflammation in the liver. Gastroenterology 143, 1158-1172 (2012).
3. Maher, J. J. DAMPs ramp up drug toxicity. J. Clint. Invest. 119, 246-249 (2009).
4. Brenner, C., Galluzzi, L., Kepp, O. & Kroemer, G. Decoding cell death signals in liver inflammation. J. Hepatol. 59, 583-594 (2013).
5. Imaeda, A. B. et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clint. Invest. 119, 305-314 (2009).
6. Marques, P. E. et al.Hepatic DNAdeposition drives drug-induced liver injury and inflammation in mice. Hepatology 61, 348-360 (2015).
7. Hoque, R. et al. 2012. P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1171-1179 (2012).
8. Wang, X., Sun, R.,Wei, H. & Tian, Z. High-mobility group box 1 (HMGB1)-Tolllike receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damageassociated lethal hepatitis: Interaction of cd T cells with macrophages. Hepatology 57, 373-384 (2013).
9. Cai, C. et al. Benzyl alcohol attenuates acetaminophen-induced acute liver injury in a toll-like receptor-4 dependent pattern in mice. Hepatology 60, 990-1002 (2014).
10. Xu, J., Zhang, X., Monestier, M., Esmon, N. L. & Esmon, C. T. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J. Immunol. 187, 2626-2631 (2011).
11. Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114-119 (2001).
12. Yohe, H. C. et al. Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1269-1279 (2006).
13. Shah, N. et al. Role of toll-like receptor 4 in mediating multiorgan dysfunction in mice with acetaminophen induced acute liver failure. Liver Transpl. 19, 751-761 (2013).
14. Cavassani, K. A. et al. Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity. PLoS One 8, e65899 (2013).
15. Jaeschke, H., Williams, C. D., Ramachandran, A. & Bajt, M. L. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 32, 8-20 (2012).
16. Ju, C. et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol. 15, 1504-1513 (2002).
17. Connolly, M. K. et al. Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology 54, 959-968 (2011).
18. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
19. Chen, C. J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851-856 (2007).
20. Williams, C. D., Farhood, A. & Jaeschke, H. Role of caspase-1 and interleukin- 1beta in acetaminophen-induced hepatic inflammation and liver injury. Toxicol. Appl. Pharmacol. 247, 169-178 (2010).
21. Ishibe, T. et al. Reduced acetaminophen-induced liver injury in mice by genetic disruption of IL-1 receptor antagonist. Lab. Invest. 89, 68-79 (2009).
22. Towne, J. E. & Sims, J. E. IL-36 in psoriasis. Curr. Opin. Pharmacol. 12, 486-490 (2012).
23. Dinarello, C. et al. IL-1 family nomenclature. Nat. Immunol. 11, 973 (2010).
24. Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36a, IL-36b, and IL-36c) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594-42602 (2011).
25. Towne, J. E., Garka, K. E., Renshaw, B. R., Virca, G. D. & Sims, J. E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 279, 13677-13688 (2004).
26. Bachmann,M., Scheiermann, P., Härdle, L., Pfeilschifter, J. &Mühl, H. IL-36c/IL- 1F9, an innate T-bet target in myeloid cells. J. Biol. Chem. 287, 41684-41696 (2012).
27. Vigne, S. et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 118, 5813-5823 (2011).
28. Johnston, A. et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186, 2613-2622 (2011).
29. Chustz, R. T. et al. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 45, 145-153 (2011).
30. van de Veerdonk, F. L. et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 109, 3001-3005 (2012).
31. Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204, 2603-2614 (2007).
32. Tortola, L. et al. Psoriasiform dermatitis is driven by IL-36-mediated DCkeratinocyte crosstalk. J. Clin. Invest. 122, 3965-3976 (2012).
33. Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620-628 (2011).
34. Scheiermann, P. et al. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am. J. Pathol. 182, 1107-1113 (2013).
35. Feng, D. et al. Acute and Chronic Effects of IL-22 on Acetaminophen-Induced Liver Injury. J. Immunol. 193, 2512-2518 (2014).
36. Dragomir, A. C., Sun, R., Choi, H., Laskin, J.D.&Laskin, D. L. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J. Immunol. 189, 5934-5941 (2012).
37. Henderson, N. C. et al. Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut 56, 982-990 (2007).
38. Liu, Z. X., Govindarajan, S. & Kaplowitz, N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127, 1760-1774 (2004).
39. Ishida, Y. et al. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J. 16, 1227-1236 (2002).
40. Foster, A. M. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053-6061 (2014).
41. Shimizu, Y. et al. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 34, 311-319 (2001).
42. Michael, S. L., Pumford, N. R., Mayeux, P. R., Niesman, M. R. & Hinson, J. A. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 30, 186-195 (1999).
43. Garlanda, C., Riva, F., Bonavita, E., Gentile, S. & Mantovani, A. Decoys and Regulatory Receptors of the IL-1/Toll-Like Receptor Superfamily. Front. Immunol. 4, 180 (2013).
44. Costelloe, C. et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J. Neurochem. 105, 1960-1969 (2008).
45. Gunawan, B. K. et al. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131, 165-178 (2006).
46. Ryan, P. M. et al. Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice. Chem. Res. Toxicol. 25, 83-93 (2012).
47. Lee, A. Y., Eri, R., Lyons, A. B.,Grimm, M. C. &Korner, H. CC Chemokine Ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil? Front. Immunol. 4, 194 (2013).
48. Hammerich, L. et al. Chemokine receptor CCR6-dependent accumulation of cd T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59, 630-642 (2014).
49. Zhu, X. & Uetrecht, J. A novel T(H)17-type cell is rapidly increased in the liver in response to acetaminophen-induced liver injury: T(H)17 cells and the innate immune response. J. Immunotoxicol. 10, 287-291 (2013).
50. Rao, R. et al. Interleukin 17-Producing cdT Cells Promote Hepatic Regeneration in Mice. Gastroenterology 147, 473-484 (2014).
51. Erhardt, A., Biburger, M., Papadopoulos, T. & Tiegs, G. IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology 45, 475-485 (2007).
52. Bourdi, M. et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35, 289-298 (2002).
53. Affo, S. et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63, 1782-1792 (2014).
54. Shen, K. et al.Depletion of activated hepatic stellate cell correlates with severe liver damage and abnormal liver regeneration in acetaminophen-induced liver injury. Acta. Biochim. Biophys. Sin. (Shanghai) 43, 307-315 (2011).
55. Yin, C., Evaso, K. J., Asahina, K. & Stainier, D. Y. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 123, 1902-1910 (2013).
56. Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 14, 156-165 (2008).
57. Gao, B., Wang, H., Lafdil, F. & Feng, D. STAT proteins - key regulators of antiviral responses, inflammation, and tumorigenesis in the liver. J. Hepatol. 57, 430-441 (2012).
58. James, L. P., Lamps, L. W., McCullough, S. & Hinson, J. A. Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse. Biochem. Biophys. Res. Commun. 309, 857-863 (2003).
59. Masubuchi, Y. et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun. 304, 207-212 (2003).
60. Haupenthal, J. et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 14, 410-419 (2012).